Pillar® ONCO/Reveal™ Lung Fusion RNA Panel

The ONCO/Reveal Lung Fusion Panel is a robust NGS assay that interrogates multiple gene rearrangement regions of interest* across non-small cell lung cancer (NSCLC) samples. The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.

Panel highlights

Specifically targets non-small cell lung cancer-related genes

Detects fusions from 8 kinase genes plus >30 partner genes and MET14 exon skipping

Compatible with RNA from FFPE or tissue

Streamlined workflow: from RNA to sequencer in 1 day 

For research use only. Not for use in diagnostic procedures.

Panel targets

Kinase (exon) Partner gene (exon)
ALK(19,20) CLTC(31), EML4(2,3,6,13,14,15,17,18,20), HIP1(21,28,30), KIF5B(15,17,24), KLC1(9), MSN(11), STRN(3), TGF(4,5,6), TPM3(8), TPR(15)
FGFR3(17,18) TACC3(4,8,9,10,11)
NRG1(4,6) CD74(6,8), SLC3A2(5), VAMP2(4)
NTRK1(10,12,13) CD74(3,8), MPRIP(14,18,21), TGF(5), TPM3(8), TPR(6,21)
RET(8,11,12) CCDC6(1), CUX1(10), KIF5B(15,16,22,23,24), NCOA4(7), TRIM33(11,14)
ROS1(32,34,35,36) CCDC6(5), CD74(6), CLTC(31), EZR(10), GOPC(4,8), LRIG3(16), MSN(9), SDC4(2,4), SLC34A2(4,13), TGF(4), TPM3(8)
MET(15) KIF5B(24)
MET exon 14 skipping

Panel specifications

Enrichment chemistry Multiplex PCR using tiled amplicons
Number of pools 1 pool
Number of genes/fusions 8/92 plus MET 14 exon skipping
Variant types Fusion RNA transcripts
Average amplicon size 141bp
Recommended RNA input range 10ng to 50ng
Sample type RNA from FFPE or tissue
Total assay time (from sample to sequencer) <9-10 hours
Sequencing platforms Illumina® and MGISEQ™

See the data

Development and Evaluation of a Lung Cancer Fusion NGS Panel


Concordant fusion detection

In 40 samples (clinical, cell lines, and references) with known variants, all known fusions that included ALK, ROS1, RET, NTRK1, and MET exon 14 alterations were detected without false positives. In 25 clinical samples, 10 ALK fusion targeted breakpoints were detected, 1 RET fusion was called by expression imbalance, and 1 sample had MET exon 14 skipping.

Lodato et al. Development and evaluation of a lung cancer fusion NGS panel. Poster presented at the Next Generation Dx Summit 2018.

Pillar technology

Pillar provides a seamlessly integrated NGS workflow, from panel design to data analysis.


icon of ampPD primer as located on DNA

Primer design platform for reliable amplicon specificity


test tube icon

Enrichment chemistry that enables single-tube amplification


PiVat icon

Bioinformatic tools that deliver sensitive, robust variant calls

Contact an expert

Contact us for technical information or to get a quote

WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top